Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 12, 2009, Pages 5522-5528

  Li, Haochuan ^a   Yang, Wanhua ^a   Chen, Peter W ^a   Alizadeh, Hassan ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; SMALL INTERFERING RNA; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER METASTASIS; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; UVEA MELANOMA; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DISEASE MODEL; DRUG EFFECT; GENETICS; LIVER TUMOR; MELANOMA; METASTASIS; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; UVEA TUMOR;

ANIMALS; CELL MOVEMENT; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 73349084970     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3804     Document Type: Article

References (46)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologicaspects of uveal melanoma. Surv Ophthalmol. 1988;32:239-251
2. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995; 76:1665-1670.
3. Albert DM. The ocular melanoma story: LIII Edward Jackson Memorial Lecture, part II. Am J Ophthalmol. 1997;123:729-741.
4. Gombos DS, Mieler WF. Therapy of uveal melanoma: methods and risk factors associated with treatment. In: Albert DM, Polans A, ed. Ocular Oncology. New York: Marcel Dekker, Inc.; 2003:321-352.
5. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA. 1989;86:641-644.
6. Augsburger JJ, Mullen D, Kleineidam M. Planned combined I-125 plaque irradiation and indirect ophthalmoscope laser therapy for choroidal malignant melanoma. Ophthalmic Surg. 1993;24:76-81.
7. COMS. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthal-mol. 2001;119:670-676.
8. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma [see comments]. Cancer. 1993;72:2219-2223.
9. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571-573.
10. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006; 107:1761-1767.
11. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 2006;79:639-651.
12. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98:1652-1658.
13. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
14. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119:2026- 2029.
15. Li H, Alizadeh H, Niederkorn JY. Differential expression of chemo-kine receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci. 2008;49:636-643.
16. Scala S, Ierano C, Ottaiano A, et al. CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother. 2007; 56:1589-1595.
17. Reinmuth N, Liu W, Ahmad SA, et al. av/33 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003;63:2079-2087.
18. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002;62:7328-7334.
19. Hong JS, Pai HK, Hong KO, et al. CXCR-4 knockdown by small interfering RNA inhibits cell proliferation and invasion of oral squamous cell carcinoma cells. J Oral Pathol Med. 2009;38:214-219
20. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006;103:226-233
21. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744-2753.
22. Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res. 2000;6:3530-3535.
23. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6:459-469.
24. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835-1841.
25. Giles R, Loberg RD. Can we target the chemokine network for cancer therapeutics? Curr Cancer Drug Targets. 2006;6:659-670.
26. Khan A, Greenman J, Archibald SJ. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Curr Med Chem. 2007;14:2257-2277.
27. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540-550.
28. Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/ CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201-211.
29. Lee CH, Kakinuma T, Wang J,et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 2006;5:2592-2599
30. Arya M, Ahmed H, Silhi N, Williamson M, Patel HR. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol. 2007;28:123-131
31. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003;2:581-587.
32. De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem. 2005;5:805-824.
33. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hemato-poietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728-2730.
34. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100:13513-13518.
35. Ierano C, Giuliano P, D'Alterio C, et al. A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. Cell Cycle. 2009;8:1228-1237.
36. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967-971.
37. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64: 8604-8612.
38. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 2007;1:241-242.
39. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-323.
40. Ma D, Niederkorn JY. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci. 1998;39:1067-1075.
41. Donoso LA, Shields JA, Augsburger JJ, Orth DH, Johnson P. Meta-static uveal melanoma: diffuse hepatic metastasis in a patient with concurrent normal serum liver enzyme levels and liver scan. Arch Ophthalmol. 1985;103:758.
42. Feldman ED, Pingpank JF, Alexander HR. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol. 2004;11:290-297.
43. Rusciano D, Lin S, Lorenzoni P, Casella N, Burger MM. Influence of hepatocyte growth factor/scatter factor on the metastatic pheno-type of B16 melanoma cells. Tumour Biol. 1998;19:335-345.
44. Rusciano D, Lorenzoni P, Burger M. Murine models of liver metastasis. Invasion Metast. 1994;14:349-361.
45. Rusciano D, Lorenzoni P, Burger MM. Paracrine growth response as a major determinant in liver-specific colonization by in vivo selected B16 murine melanoma cells. Invasion Metast. 1993;13: 212-224.
46. Hendrix MJ, Seftor EA, Seftor RE, et al. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/ scatter factor (HGF/SF). Am J Pathol. 1998;152:855-863.